Loading...
•
Sep 30, 2021
Bioxcel Therapeutics Q3 2021 Earnings Report
Announced third quarter 2021 financial results and provided an update on key strategic initiatives.
Key Takeaways
BioXcel Therapeutics reported a net loss of $26.8 million for the third quarter of 2021, with cash and cash equivalents totaling approximately $252.9 million as of September 30, 2021. The company is progressing with commercial and launch readiness for BXCL501 and advancing its neuroscience and immuno-oncology franchises.
Plans for commercial and launch readiness advancing for BXCL501 orally dissolving film, ahead of January 5, 2022 PDUFA date.
On track to initiate Phase 3 program for acute treatment of agitation in patients with Alzheimer’s disease in Q4 2021.
Strengthened neuroscience franchise with indication expansion for BXCL501 in major depressive disorder (MDD).
Demonstrated encouraging anti-tumor activity and favorable safety profile for BXCL701 in combination with KEYTRUDA® in mCRPC patients with adenocarcinoma; expansion of Phase 2 trial in SCNC cohort.